BioCentury
ARTICLE | Company News

IQWiG rebuffs BindRen

July 2, 2013 12:35 AM UTC

Germany's Institute for Quality and Efficiency in Healthcare (IQWiG) said in a preliminary benefit assessment that BindRen colestilan from Mitsubishi Tanabe Pharma Corp. (Tokyo:4508; Osaka:4508) is worse than sevelamer to treat hyperphosphatemia in patients with stage 5 chronic kidney disease (CKD) receiving hemodialysis or peritoneal dialysis for whom a calcium- or aluminum-containing phosphate binder is contraindicated. IQWiG said BindRen has "no additional benefit" vs. calcium- or aluminum-containing phosphate binders because Mitsubishi did not submit "relevant" data. ...